320 related articles for article (PubMed ID: 35977298)
1. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.
Eberly LA; Yang L; Essien UR; Eneanya ND; Julien HM; Luo J; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
JAMA Health Forum; 2021 Dec; 2(12):e214182. PubMed ID: 35977298
[TBL] [Abstract][Full Text] [Related]
2. Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US.
Eberly LA; Yang L; Eneanya ND; Essien U; Julien H; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
JAMA Netw Open; 2021 Apr; 4(4):e216139. PubMed ID: 33856475
[TBL] [Abstract][Full Text] [Related]
3. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
Nanna MG; Kolkailah AA; Page C; Peterson ED; Navar AM
JAMA Cardiol; 2023 Jan; 8(1):89-95. PubMed ID: 36322056
[TBL] [Abstract][Full Text] [Related]
4. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
[TBL] [Abstract][Full Text] [Related]
5. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.
Tan X; Liang Y; Rajpura JR; Yedigarova L; Noone J; Xie L; Inzucchi S; de Havenon A
Cardiovasc Diabetol; 2023 Nov; 22(1):319. PubMed ID: 37985992
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
Luo J; Feldman R; Callaway Kim K; Rothenberger S; Korytkowski M; Hernandez I; Gellad WF
JAMA Netw Open; 2023 Jun; 6(6):e2317886. PubMed ID: 37307000
[TBL] [Abstract][Full Text] [Related]
7. Racial/Ethnic and Socioeconomic Disparities in Management of Incident Paroxysmal Atrial Fibrillation.
Eberly LA; Garg L; Yang L; Markman TM; Nathan AS; Eneanya ND; Dixit S; Marchlinski FE; Groeneveld PW; Frankel DS
JAMA Netw Open; 2021 Feb; 4(2):e210247. PubMed ID: 33635328
[TBL] [Abstract][Full Text] [Related]
8. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure.
Cromer SJ; Lauffenburger JC; Levin R; Patorno E
Diabetes Care; 2023 Jan; 46(1):65-74. PubMed ID: 36383481
[TBL] [Abstract][Full Text] [Related]
9. Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease.
Trueman C; Shin E; Donovan A; McAdam-Marx C; Coan C
J Manag Care Spec Pharm; 2023 Dec; 29(12):1275-1283. PubMed ID: 38058135
[TBL] [Abstract][Full Text] [Related]
10. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
He L; Wang J; Ping F; Yang N; Huang J; Li Y; Xu L; Li W; Zhang H
JAMA Intern Med; 2022 May; 182(5):513-519. PubMed ID: 35344001
[TBL] [Abstract][Full Text] [Related]
11. Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
Nair R; Mody R; Yu M; Cowburn S; Konig M; Prewitt T
Diabetes Ther; 2022 Dec; 13(11-12):1921-1932. PubMed ID: 36131064
[TBL] [Abstract][Full Text] [Related]
12. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
[TBL] [Abstract][Full Text] [Related]
13. Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020.
Mittman BG; Le P; Payne JY; Ayers G; Rothberg MB
Curr Med Res Opin; 2024 Mar; 40(3):377-383. PubMed ID: 38193509
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.
Yen FS; Hou MC; Cheng-Chung Wei J; Shih YH; Hsu CY; Hsu CC; Hwu CM
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1255-1264.e18. PubMed ID: 37331413
[TBL] [Abstract][Full Text] [Related]
15. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes.
Yen FS; Hou MC; Wei JC; Shih YH; Hwu CM; Hsu CC
BMC Med; 2024 Jan; 22(1):8. PubMed ID: 38172833
[TBL] [Abstract][Full Text] [Related]
16. Racial, Ethnic, and Socioeconomic Inequities in the Prescription of Direct Oral Anticoagulants in Patients With Venous Thromboembolism in the United States.
Nathan AS; Geng Z; Dayoub EJ; Khatana SAM; Eberly LA; Kobayashi T; Pugliese SC; Adusumalli S; Giri J; Groeneveld PW
Circ Cardiovasc Qual Outcomes; 2019 Apr; 12(4):e005600. PubMed ID: 30950652
[TBL] [Abstract][Full Text] [Related]
17. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment.
Stenberg E; Näslund E
Int J Obes (Lond); 2023 Apr; 47(4):251-256. PubMed ID: 36670155
[TBL] [Abstract][Full Text] [Related]
18. Ethnic/Racial and Geographic Disparities on Major Cardiovascular Events in Glucagon Like Peptide-1 receptor Agonists Trials: A Meta-Analysis.
Lavalle Cobo A; Masson W; Lobo M; Barbagelata L; Forte E; Corral P; Nogueira JP
Curr Probl Cardiol; 2023 Nov; 48(11):101940. PubMed ID: 37422042
[TBL] [Abstract][Full Text] [Related]
19. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
Schechter M; Melzer Cohen C; Fishkin A; Rozenberg A; Yanuv I; Sehtman-Shachar DR; Chodick G; Clark A; Abrahamsen TJ; Lawson J; Karasik A; Mosenzon O
Cardiovasc Diabetol; 2023 May; 22(1):126. PubMed ID: 37244998
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
